July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Clinical Application of Matrix Metalloproteinase 9 Test Using Immunoassay Kit
Author Affiliations & Notes
  • In Boem Chang
    Sanggye Paik Hospital, Inje University, Seoul, Korea (the Republic of)
  • Jae Yong Park
    Sanggye Paik Hospital, Inje University, Seoul, Korea (the Republic of)
  • Jae Suk Kim
    Sanggye Paik Hospital, Inje University, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   In Boem Chang, None; Jae Yong Park, None; Jae Suk Kim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4858. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      In Boem Chang, Jae Yong Park, Jae Suk Kim; Clinical Application of Matrix Metalloproteinase 9 Test Using Immunoassay Kit. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4858.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the clinical usefulness of InflammaDry, which measures matrix metalloproteinase 9 (MMP-9) in the tear film, at the time of diagnosis and during follow up period in patients with dry eye disease (DED).

Methods : Both eyes of patients with DED were included. The tear film was analyzed for MMP-9 by a commercially available test (InflammaDry; Rapid Pathogen Screening, Inc, Sarasota, FL) detecting levels of more than 40ng/ml. Ocular surface disease index (OSDI) score, corneal staining, tear film break-up time (TBUT) and Schirmer test results were also evaluated. These findings were correlated to results of the MMP-9 test. After the evaluation, cyclosporine 0.5mg/mL was administered twice a day and the results were compared one month later by repeating the above tests.

Results : 78 eyes of 39 patients were included, and 42 eyes of 21 patients were evaluated the same tests after 1 month. In 63 eyes (80.8%) of 78 eyes, the MMP-9 results were positive. In 34 eyes (80.9%) positive for MMP-9 before administered cyclosporine 0.5mg/mL, levels of MMP-9 were decreased (p=0.001), improved corneal erosion (p<0.001), increased TBUT (p<0.001) and improved Schirmer test was also improved (p=0.014) after administered cyclosporine 0.5mg/mL for 1 month. In contrast, 8 eyes (19.1%) were negative for MMP-9 before administered cyclosporine 0.5mg/mL, levels of MMP-9 were increased(p=0.020) after use of cyclosporine 0.5mg/mL for 1 month. Corneal staining, TBUT and Schirmer test results were not significantly different from the before using cyclosporine.

Conclusions : If the InflammaDry test is positive in the patients with DED, treatment with cyclosporine will be more effective. So, performing an InflammaDry test before beginning cyclosporine therapy may be helpful in predicting prognosis.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×